Literature DB >> 21674417

ANCA: associated lung fibrosis.

Hidehiro Yamada1.   

Abstract

The possible link between pulmonary fibrosis, anti-neutrophil cytoplasmic autoantibody (ANCA) positivity, and vasculitis is poorly understood. During the past 6 years, five retrospective case-control studies have been published. These studies suggest that pulmonary fibrosis (PF) is an underestimated manifestation of ANCA-associated vasculitis. Common clinical characteristics include older age (around 70 years), constant positivity of myeloperoxidase (MPO)-ANCA and the poor prognosis of the pulmonary disease. The diagnosis of PF often predates the development of vasculitis. There are no significant differences of pulmonary function parameters, bronchoalveolar lavage analysis, or high-resolution computed tomographic (HRCT) findings between ANCA-associated PF and idiopathic pulmonary fibrosis (IPF). The high mortality rate of ANCA-associated PF indicates that a search for ANCAs should be performed at diagnosis in every patient with PF because the presence of ANCAs increases the risk of development of vasculitis and should promote specific monitoring of patients with positive MPO-ANCA. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674417     DOI: 10.1055/s-0031-1279828

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  13 in total

Review 1.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

2.  Monitoring with serum SP-A, SP-D, and KL-6 in a patient with interstitial pneumonia complicated with ANCA-associated glomerulonephritis.

Authors:  Fumihiko Takahashi; Eriko Miura; Kiyoko Shibukawa; Junko Chinda; Naoyuki Miyokawa; Chieko Imamoto; Kenjiro Kikuchi; Naoyuki Hasebe
Journal:  CEN Case Rep       Date:  2013-03-18

3.  Microscopic polyangiitis associated with pulmonary fibrosis.

Authors:  Marcelo Fernandez Casares; Alejandra Gonzalez; Mariano Fielli; Flavia Caputo; Yanina Bottinelli; Marcelo Zamboni
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

4.  Elevated serum levels of two anti-neutrophil cytoplasmic antibodies in a lung cancer patient: A case report.

Authors:  Shinichiro Okauchi; Tomohiro Tamura; Katsunori Kagohashi; Mio Kawaguchi; Hiroaki Satoh
Journal:  Biomed Rep       Date:  2016-09-06

5.  Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury.

Authors:  Vanessa J Craig; Pablo A Quintero; Susanne E Fyfe; Avignat S Patel; Martin D Knolle; Lester Kobzik; Caroline A Owen
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

6.  Diagnostic value of antineutrophil cytoplasmic antibodies in children with bronchiolitis obliterans.

Authors:  Dehui Chen; Na Xie; Yuneng Lin; Zifeng Yang; Wenkuan Liu; Shangzhi Wu; Jingbin Chen; Xiaoan Pan; Shaolin Yang; Yong Cai
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 7.  Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist.

Authors:  Sakae Homma; Aika Suzuki; Keita Sato
Journal:  Clin Exp Nephrol       Date:  2012-11-28       Impact factor: 2.801

Review 8.  Limited pulmonary MPA, a new MPA entity? A rheumatologist's perspective.

Authors:  Luis F Flores-Suárez
Journal:  Clin Exp Nephrol       Date:  2012-11-28       Impact factor: 2.801

9.  Pulmonary Limited MPO-ANCA Microscopic Polyangiitis and Idiopathic Lung Fibrosis in a Patient with a Diagnosis of IgA Nephropathy.

Authors:  Alwin Tilanus; Patricia Van der Niepen; Caroline Geers; Karl Martin Wissing
Journal:  Case Rep Nephrol       Date:  2015-07-22

10.  Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis.

Authors:  Tidi M Hassan; Astrid S Hassan; Ann Igoe; Mark Logan; Cedric Gunaratnam; Noel G McElvaney; Shane J O'Neill
Journal:  BMC Immunol       Date:  2014-05-27       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.